BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights
– Completed positive End-of-Phase 2 meeting with the Food and Drug Administration (“FDA”) and received scientific advice from the European Medicines Agency (“EMA”) to support design of its CALM Phase 3 program, which is expected to initiate in Q4 2022 – – Ended second quarter 2022 with approximately US$384.6 million in pro-forma cash, cash equivalents … [Read more…]
